Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973151 | 0.93 | OPRM1 (0.41) | DNM1TSHRCA2OPRM1CA1 | |
| SCHEMBL1969358 | 0.85 | TSHR (0.31) | TSHR | |
| SCHEMBL17607404 | 0.82 | TSHR (0.31) | DNM1TSHRSMN1; SMN2CA2MAPK1 | |
| SCHEMBL7756753 | 0.80 | DNM1 (0.36) | DNM1TSHRSMN1; SMN2CA2MAPK1 | |
| SCHEMBL21989957 | 0.78 | DNM1 (0.35) | DNM1TSHRSMN1; SMN2CA2MAPK1 | |
| SCHEMBL11662652 | 0.77 | CA2 (0.34) | DNM1TSHRSMN1; SMN2CA2MAPK1 | |
| SCHEMBL17607609 | 0.77 | TSHR (0.31) | DNM1TSHRSMN1; SMN2CA2MAPK1 | |
| SCHEMBL5984313 | 0.77 | — | — | |
| SCHEMBL8380926 | 0.76 | ALDH1A1 (0.39) | DNM1TSHRSMN1; SMN2CA2MAPK1 | |
| SCHEMBL1971978 | 0.75 | DNM1 (0.36) | DNM1TSHRSMN1; SMN2CA2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194371-B1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY SCIENCE TECH & RES (SG) | 2020-09-02 | — | — | EP | disclosed |
| US-10570097-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-02-25 | — | — | US | disclosed |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-17 | — | — | US | disclosed |
| US-10160728-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-12-25 | — | — | US | disclosed |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-10-12 | — | — | US | disclosed |
| CN-107108518-A | Antibacterial imidazolium compounds | 新加坡科技研究局 | 2017-08-29 | — | — | CN | disclosed |
| EP-3194371-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | Agency for Science, Technology and Research (SG) | 2017-07-26 | — | — | EP | disclosed |
| US-9469662-B2 | Process for preparing optically active biophosphinylalkanes | BASF SE (DE) | 2016-10-18 | — | — | US | disclosed |
| WO-2016043660-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-24 | — | — | WO | disclosed |
| EP-1913007-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2011-06-22 | — | — | EP | disclosed |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1913007-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007012655-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570097-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | DNM1 707/4885TSHR 3989/4885SMN1; SMN2 4220/4885 |
| US-10160728-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | DNM1 707/4885TSHR 3989/4885SMN1; SMN2 4220/4885 |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | DNM1 707/4885TSHR 3989/4885SMN1; SMN2 4220/4885 |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | DNM1 707/4885TSHR 3989/4885SMN1; SMN2 4220/4885 |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | PHOSPHO1, DCTPP1, DCPS | DNM1 57/4885TSHR 4357/4885SMN1; SMN2 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.